Back to search

Article

Mutations in <i>fbiD (Rv2983)</i> as a novel determinant of resistance to pretomanid and delamanid in <i>Mycobacterium tuberculosis</i>

2020-09-11

Abstract excerpt

<h4>ABSTRACT</h4> The nitroimidazole pro-drugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis , but clinical evidence is limited to date. We selected pretomanid-resistant M. tuberculosis mutants in two mouse models of TB...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d8de4d38-cfcb-5c31-b323-3d22774ad7fb
DOI
10.1101/2020.09.10.292508
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mutations in <i>fbiD (Rv2983)</i> as a novel determinant of resistance to pretomanid and delamanid in <i>Mycobacterium tuberculosis</i>DOI 10.1101/2020.09.10.292508
Select a neighboring publication to make it the new centre.